MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Bayer AG

Затворен

СекторФинансови

26.36 -0.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.3

Максимум

26.425

Ключови измерители

By Trading Economics

Приходи

1.6B

1.3B

Продажби

2B

14B

P/E

Средно за сектора

30.9

24.968

EPS

2.49

Дивидентна доходност

0.44

Марж на печалбата

9.492

Служители

90,885

EBITDA

1.9B

3.6B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+0.53% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.44%

4.18%

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.5B

25B

Предишно отваряне

26.53

Предишно затваряне

26.36

Настроения в новините

By Acuity

37%

63%

139 / 538 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Bayer AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2025 г., 08:22 ч. UTC

Печалби
Значими двигатели на пазара

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13.05.2025 г., 06:09 ч. UTC

Печалби

Bayer Confirms Guidance Despite Net Profit Drop

24.03.2025 г., 09:37 ч. UTC

Значими двигатели на пазара

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5.06.2025 г., 08:29 ч. UTC

Пазарно говорене

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30.05.2025 г., 13:47 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27.05.2025 г., 12:22 ч. UTC

Пазарно говорене
Печалби

Bayer's Prospects Are Improving -- Market Talk

16.05.2025 г., 13:42 ч. UTC

Горещи акции

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16.05.2025 г., 08:57 ч. UTC

Горещи акции

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15.05.2025 г., 22:46 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13.05.2025 г., 06:50 ч. UTC

Пазарно говорене
Печалби

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13.05.2025 г., 05:36 ч. UTC

Печалби

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13.05.2025 г., 05:35 ч. UTC

Печалби

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13.05.2025 г., 05:34 ч. UTC

Печалби

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13.05.2025 г., 05:34 ч. UTC

Печалби

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13.05.2025 г., 05:32 ч. UTC

Печалби

Bayer 1Q EPS EUR2.49

13.05.2025 г., 05:32 ч. UTC

Печалби

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13.05.2025 г., 05:32 ч. UTC

Печалби

Bayer 1Q Ebitda Before Special Items EUR4.085B

13.05.2025 г., 05:31 ч. UTC

Печалби

Bayer 1Q EBIT EUR2.32B

13.05.2025 г., 05:31 ч. UTC

Печалби

Bayer 1Q Net Pft EUR1.30B

13.05.2025 г., 05:31 ч. UTC

Печалби

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13.05.2025 г., 05:30 ч. UTC

Печалби

Analysts Saw Bayer 1Q Sales at EUR13.41B

13.05.2025 г., 05:30 ч. UTC

Печалби

Bayer 1Q Sales EUR13.74B

13.05.2025 г., 05:30 ч. UTC

Печалби

Bayer Backs 2025 View

14.04.2025 г., 13:00 ч. UTC

Топ новини

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7.04.2025 г., 17:01 ч. UTC

Пазарно говорене

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10.03.2025 г., 08:38 ч. UTC

Пазарно говорене

Bayer's Partial Recovery Is in Sight -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Bayer AG Прогноза

Ценова цел

By TipRanks

0.53% нагоре

12-месечна прогноза

Среден 26.58 EUR  0.53%

Висок 33 EUR

Нисък 20 EUR

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Bayer AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

3

Купи

10

Задържане

0

Продай

Техническа оценка

By Trading Central

22.99 / 23.88Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

139 / 538 Класиране в Финансови

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.